Liver transplantation in an infant with cerebrotendinous xanthomatosis, cholestasis, and rapid evolution of liver failure.
CYP27A1
bile acid synthesis disorders
cerebrotendinous xanthomatosis
liver transplantation
neonatal cholestasis
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
23
04
2022
received:
13
12
2021
accepted:
05
05
2022
pubmed:
29
5
2022
medline:
13
8
2022
entrez:
28
5
2022
Statut:
ppublish
Résumé
Cerebrotendinous xanthomatosis (CTX) is a disorder of bile acid (BA) metabolism due to biallelic mutations in CYP27A1. The deposition of cholesterol and cholestanol in multiple tissues results, manifesting as neurologic disease in adults or older children. Neonatal cholestasis (NC) as a presentation of CTX is rare; it may self-resolve or persist, evolving to require liver transplantation (LT). We present in the context of similar reports an instance of CTX manifest as NC and requiring LT. A girl aged 4mo was evaluated for NC with normal serum gamma-glutamyl transpeptidase activity. An extensive diagnostic work-up, including liver biopsy, identified no etiology. Rapid progression to end-stage liver disease required LT aged 5mo. The explanted liver showed hepatocyte loss and micronodular cirrhosis. Bile salt export pump (BSEP), encoded by ABCB11, was not demonstrable immunohistochemically. Both severe ABCB11 disease and NR1H4 disease-NR1H4 encodes farsenoid-X receptor, necessary for ABCB11 transcription-were considered. However, selected liver disorder panel sequencing and mass-spectrometry urinary BA profiling identified CTX, with homozygosity for the predictedly pathogenic CYP27A1 variant c.646G > C p.(Ala216Pro). Variation in other genes associated with intrahepatic cholestasis was not detected. Immunohistochemical study of the liver-biopsy specimen found marked deficiency of CYP27A1 expression; BSEP expression was unremarkable. Aged 2y, the girl is free from neurologic disease. Bile acid synthesis disorders should be routinely included in the NC/"neonatal hepatitis" work-up. The mutually supportive triple approach of BA profiling, immunohistochemical study, and genetic analysis may optimally address diagnosis in CTX, a treatable disease with widely varying presentation.
Sections du résumé
BACKGROUND
Cerebrotendinous xanthomatosis (CTX) is a disorder of bile acid (BA) metabolism due to biallelic mutations in CYP27A1. The deposition of cholesterol and cholestanol in multiple tissues results, manifesting as neurologic disease in adults or older children. Neonatal cholestasis (NC) as a presentation of CTX is rare; it may self-resolve or persist, evolving to require liver transplantation (LT).
METHODS
We present in the context of similar reports an instance of CTX manifest as NC and requiring LT.
RESULTS
A girl aged 4mo was evaluated for NC with normal serum gamma-glutamyl transpeptidase activity. An extensive diagnostic work-up, including liver biopsy, identified no etiology. Rapid progression to end-stage liver disease required LT aged 5mo. The explanted liver showed hepatocyte loss and micronodular cirrhosis. Bile salt export pump (BSEP), encoded by ABCB11, was not demonstrable immunohistochemically. Both severe ABCB11 disease and NR1H4 disease-NR1H4 encodes farsenoid-X receptor, necessary for ABCB11 transcription-were considered. However, selected liver disorder panel sequencing and mass-spectrometry urinary BA profiling identified CTX, with homozygosity for the predictedly pathogenic CYP27A1 variant c.646G > C p.(Ala216Pro). Variation in other genes associated with intrahepatic cholestasis was not detected. Immunohistochemical study of the liver-biopsy specimen found marked deficiency of CYP27A1 expression; BSEP expression was unremarkable. Aged 2y, the girl is free from neurologic disease.
CONCLUSIONS
Bile acid synthesis disorders should be routinely included in the NC/"neonatal hepatitis" work-up. The mutually supportive triple approach of BA profiling, immunohistochemical study, and genetic analysis may optimally address diagnosis in CTX, a treatable disease with widely varying presentation.
Substances chimiques
Bile Acids and Salts
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14318Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem. 1991;266(12):7779-7783.
Lorincz MT, Rainier S, Thomas D, Fink JK. Cerebrotendinous xanthomatosis - Possible higher prevalence than previously recognized. Arch Neurol. 2005;62(9):1459-1463.
Clayton PT. Disorders of bile acid synthesis. J Inherit Metab Dis. 2011;34(3):593-604.
Heubi JE, Setchell KDR, Bove KE. Inborn errors of bile acid metabolism. Clin Liver Dis. 2018;22(4):671-687.
Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P. Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis. 2008;31(Suppl 2):S241-S245.
Setchell KDR, Heubi JE. Defects in bile acid biosynthesis-diagnosis and treatment. J Pediatr Gastroenterol Nutr. 2006;43(Suppl 1):S17-S22.
Mandia D, Chaussenot A, Besson G, et al. Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults. J Neurol. 2019;266(8):2043-2050.
Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol. 2013;36(3):78-83.
Clayton PT, Verrips A, Sistermans E, Mann A, Mieli-Vergani G, Wevers R. Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2002;25(6):501-513.
Degrassi I, Amoruso C, Giordano G, et al. Case report: early treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis presenting as neonatal cholestasis. Front Pediatr. 2020;8:382-387.
Berginer VM, Gross B, Morad K, et al. Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics. 2009;123(1):143-147.
Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2014;9:179-189.
Setchell KDR, O'Connell N, Russell DW. A unique case of cerebrotendinous xanthomatosis presenting in infancy with cholestatic liver disease further highlights bile acid synthetic defects as an important category of metabolic liver disease. In: Van Berge Henegouwen GP, Keppler D, Leuschner U, Paumgartner G, Stiehl A, eds. Falk symposium. Vol 120. XVI International Bile Acid Meeting Biology of Bile Acids in Health and Disease; 2000:12-13.
von Bahr S, Björkhem I, Van't Hooft F, et al. Mutation in the sterol 27-hydroxylase gene associated with fatal cholestasis in infancy. J Pediatr Gastroenterol Nutr. 2005;40(4):481-486.
Gong JY, Setchell KDR, Zhao J, et al. Severe neonatal cholestasis in cerebrotendinous xanthomatosis: genetics, immunostaining, mass spectrometry. J Pediatr Gastroenterol Nutr. 2017;65(5):561-568.
Lipiński P, Klaudel-Dreszler M, Ciara E, et al. Sterol 27-hydroxylase deficiency as a cause of neonatal cholestasis: Report of 2 cases and review of the literature. Front Pediatr. 2020;8:2296-2360.
Zhang P, Zhao J, Peng XM, Qian YY, Zhao XM, Zhou WH, Wang JS, Wu BB, Wang HJ Cholestasis as a dominating symptom of patients with CYP27A1 mutations: an analysis of 17 Chinese infants. J Clin Lipidol 2021; 15(1):116-123.
Shen CH, Wang ZX. Liver transplantation due to cerebrotendinous xanthomatosis end-stage liver disease. World J Pediatr. 2018;14:414-415.
Pietrobattista A, Veraldi S, Candusso M, et al. The contribution of plasma oxysterols in the challenging diagnostic work-up of infantile cholestasis. Clin Chim Acta. 2020;507:181-186.
Gomez-Ospina N, Potter CJ, Xiao R, et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun. 2016;7:10713.
Garuti R, Lelli N, Barozzini M, et al. Cerebrotendinous xanthomatosis caused by two new mutations of the sterol-27-hydroxylase gene that disrupt mRNA splicing. J Lipid Res. 1996;37(7):1459-1467.
Bartholdi D, Zumsteg D, Verrips A, et al. Spinal phenotype of cerebrotendinous xanthomatosis-a pitfall in the diagnosis of multiple sclerosis. J Neurol. 2004;251(1):105-107.
Boenzi S, Deodato F, Taurisano R, et al. A new simple and rapid LC-ESI-MS/MS method for quantification of plasma oxysterols as dimethylaminobutyrate esters. Its successful use for the diagnosis of Niemann-pick type C disease. Clin Chim Acta. 2014;437:93-100.
Richards S, Aziz N, Bale S, et al. ACMG laboratory quality assurance committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
Verrips A, Hoefsloot LH, Steenbergen GC, et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain. 2000;123(5):908-919.
Nicastro E, D'Antiga L. Next generation sequencing in pediatric hepatology and liver transplantation. Liver Transpl. 2018;24(2):282-293.
Jimenez-Rivera C, Nightingale S, Benchimol EI, Mazariegos GV, Ng VL. Outcomes in infants listed for liver transplantation: a retrospective cohort study using the united network for organ sharing database. Pediatr Transplant. 2016;20(7):904-911.
Pajares S, Arias A, García-Villoria J, et al. Cholestane-3β,5α,6β-triol: high levels in Niemann-pick type C, cerebrotendinous xanthomatosis, and lysosomal acid lipase deficiency. J Lipid Res. 2015;56(10):1926-1935.
Mignarri A, Gallus GN, Dotti MT, Federico A. A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2014;37(3):421-429.
Stelten BML, Huidekoper HH, van de Warrenburg BPC, et al. Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start. Neurology. 2019;92(2):e83-e95.
DeBarber AE, Kalfon L, Fedida A, et al. Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment. J Lipid Res. 2018;59(11):2214-2222.